Elucid, a Boston, MA-based medical technology company developing AI software to enable cardiovascular disease detection, raised $8M in Series A financing.
The round was led by MedTex Ventures and Global Health Impact Fund. New and existing investors Checkmate Capital, IAG Capital, BlueStone Venture Partners, University of Michigan – Wolverine Venture Fund, Willamette Valley Capital LLC, and Angel Physicians Fund also participated in the round.
The company intends to use the funds to to continue advancing its technology for non-invasive estimation of cardiovascular event risk, myocardial ischemia, and therapeutic response.
Led by CEO Blake Richards, Chief Commercial Officer Jason Bottiglieri and Founder, President, and CTO Andrew Buckler, Elucid is a medical technology company using interpretable and validated AI to provide physicians with a means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Advanced clinical insights from ElucidVivo equip physicians with critical information designed to enable precision medicine. ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.
The company recently published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts.
The ElucidVivo software is available for commercial use in the U.S. and Europe.